Study on Skin Sensitization Potential of an Anti-tumor necrosis factor-alpha receptor fusion protein in Guinea pigs

G. Selvam\(^1\)*, S. Bhuvana\(^2\), P.C. Prabu\(^3\) and K. Sadasivan Pillai\(^1\)

\(^1\)University of Madras, Chepauk, Chennai – 600 005, India
\(^2\)Department of Academics and Human Resource Development, Indian Institute of Food Processing Technology, Thanjavur – 613 005, India
\(^3\)Department of Veterinary Pathology, Madras Veterinary College, Tamilnadu Veterinary and Animal Sciences University, Chennai – 600 007, India

*Corresponding author

Abstract

Etanercept is an anti-TNF\(\alpha\) biopharmaceutical used in the treatment of several disorders of inflammation as well as autoimmune conditions. This present study was aimed to identify the skin sensitization potential of the etanercept, in guinea pigs by following Guinea Pig Maximization Test (GPMT) of Magnusson and Kligman method. The animals were divided into two groups; negative control comprising six males and 6 females and treatment groups having ten males and ten females. Through a range finding study, the dose for main study was selected as 0.5% (low concentration) and 1.0% (high concentration) of etanercept for topical induction and challenge doses. The application site was examined at 48 and 72 hours post-dosing for the presence of allergic reactions. Apart from this, animals were observed for body weight and exhibition of clinical signs of toxicity daily throughout the experimental period. At both time points of observation, no skin reaction was observed in the experimental group after the challenge. The body weights of the treated animals were found to be comparable with the control animals. Based on the results of the study, the etanercept was found to be safe and well tolerated and was concluded to be a non-sensitizer to the skin of the guinea pigs.

Keywords

Anti-TNF\(\alpha\) biopharmaceuticals, skin sensitization, preclinical safety, guinea pigs

Received: 05 May 2020
Available Online: 10 June 2020

Introduction

TNF-\(\alpha\) is identified as a key player of the vast majority of the inflammation, which are elicited in response to a wide variety of noxious stimuli like infection, tumor malignancies etc. Although the function of TNF-\(\alpha\) is more beneficial in acute cases, the over expression and the prolonged persistence of the circulating TNF-\(\alpha\) leads to continuous
activation of various normal cells resulting in induction of highly detrimental chronic diseases like rheumatoid arthritis (Weinblatt et al., 1999). Chronic cardiac diseases (Tziakas et al., 2004), etc. Several biopharmaceutical cytokine blockers against TNF family members and TNF receptors have been developed. Some of the important TNF antagonists, which have been recommended by the FDA are infliximab, etanercept, adalimumab, certolizumabpegol and golimumab (FDA, 2011).

Etanercept is a biopharmaceutical used in the treatment of several disorders of inflammation as well as autoimmunity through the inhibition of TNF-α. Disorders of autoimmunity include conditions that arise as a result of immunological response against one’s own antigens. Etanercept causes the inhibition of TNFα and thereby has the potential to treat such disorders (Feldmann and Maini, 2003). Skin sensitization is an immunologically mediated cutaneous reaction to an allergenic test substance whereby a heightened responsiveness is induced (Kimber et al., 2001). Generally, skin sensitization tests are performed for the compounds that are topically applied or that have the chance of unintentional exposure to skin surface. However, it is also warranted to the injectable substance especially for those that are injected subcutaneously as these substances stay at subcutaneous area for a sufficient period of time that facilitates the elicitation of sensitization reaction. Further, human sensitization tests are time consuming and very expensive because a large number of volunteers (around 150-200) is required for each test and moreover, the participated volunteers form an inhomogeneous test group which may alter the test data (Basketter et al., 2004).

In the assessment and evaluation of the toxic characteristics of a test substance, determination of its potential to provoke skin sensitization reactions in a homogeneous group of animal models becomes a mandate. The guinea pig maximization test (GPMT) is a more sensitive assay and have been accepted for hazard identification of skin sensitizing substances (Magnusson and Kligman, 1969 and Basketter and Scholes, 1992). The maximization test is an ‘adjuvant’ type test in which the sensitization is potentiated by the intra-dermal injection of Freund’s Complete Adjuvant. Since the recombinant etanercept is clinically intended through subcutaneous route in humans, the guinea pig maximization test was performed to assess the skin sensitization potential of etanercept in the guinea pig.

Materials and Methods

Animals & Husbandry

The guinea pig (Cavia porcellus; Dunkin Hartley) was selected as the test system as the skin of guinea pig is more similar to human skin and is historically shown to be suitable model for skin sensitization potential testing. A total of twelve guinea pigs (six males and six females) were used for range finding study. For main study, thirty two animals were divided into control (six males and six females) and treatment (ten males and ten females) groups. Prior to the start of the experiment, the animals were housed in their respective cages in experimental room for 5 days so as to acclimatize with the laboratory conditions. During the whole experimentation, the experimental room temperature was maintained between 17 and 20 °C and the relative humidity were between 45 and 60%. Temperature and relative humidity were monitored once daily. The experimental room was provided with a 12 h light and 12 h dark photoperiod cycle controlled by an automatic timer. Test room light intensity and the noise level were
maintained within 100 lux and 50db, respectively. Gamma irradiated rodent pellet feed supplied by Laboratory Animal Feed, Pune, India and clean reverse osmosis purified drinking water was provided to the animals at *ad libitum*. The experimental procedures were approved by the Institutional Animal Ethics Committee (IAEC) and Institutional Bio-safety Committee (IBSC) and the study was conducted at International Institute of Biotechnology and Toxicology, Padappai.

**Testing Method**

Guinea Pig Maximization Test (GPMT) of Magnusson and Kligman (1969) method was followed.

**Preparation of the Test Substance**

For intradermal injection, the test substance was dissolved, in a formulation buffer. For the intradermal induction phase of the main study, incorporation of the test substance in a 1:1 mixture (v/v) of FCA (Freund's Complete Adjuvant) and formulation buffer was used. For topical applications, the test substance was applied as such.

**Range Finding Study**

**Intradermal Induction**

The fur over the dorsum of the animals was neatly clipped without causing abrasion. The etanercept at 0.5% solution of 0.1ml was intradermally injected over the clipped flank region of four guinea pigs (2 males + 2 females). The injection site was examined for pathological lesions at approximately 24, 48 and 72 h and five days after intradermal injection. As there was no dermal reaction observed in animals injected with 0.5% solution of 0.1 ml of test substance, the same concentration (i.e. 0.5% solution of 0.1ml) was selected for intradermal induction phase of the main study.

The etanercept as 0.5 % solution of 0.2 ml (1 male + 1 female) and as 1.0 % solution of 0.2 ml (1 male + 1 female) was prepared and applied over the clipped area of the animals as occlusive patch. After 48 h exposure period, the degree of erythema and oedema was evaluated using the grading scale specified in Table 1. As none of the animal exhibited any skin reaction at 1, 24 and 48 h after removal of the patch, the highest concentration of 1.0% solution of 0.2 ml was selected for the topical induction and challenge phases of the main study.

**Main study**

The procedure involved treatment in two phases i.e. induction and challenge phase.

**Induction Phase of Control Group**

**Intradermal Injection**

Injections were given on day 0 using the procedures described for test group animals except that the pairs of injections were:

- **Injection 1**: 1:1 mixture (v/v) FCA/distilled water
- **Injection 2**: Formulation buffer alone
- **Injection 3**: 50% v/v formulation buffer in a 1:1 mixture (v/v) FCA/distilled water.

**Topical Application (Day 7)**

Control animals were treated identically to the test group animals with formulation buffer. Approximately 48 h after application, the occlusive dressings were removed from each control group animal. The skin reactions were evaluated approximately 1 and 24 h after dressing removal, as described for the treatment group animals.
Induction Phase of Treatment Group

Intradermal Injections (Day 0)

Prior to the administration of etanercept, a small area over the shoulder region of the animals was clipped without causing any abrasion. Three pairs of intradermal injections of 0.1 ml volume were given in the shoulder region. Injections of 0.1 ml volume of each pair lies on each side of the midline.

Injection 1: 1:1 mixture (v/v) FCA/distilled water
Injection 2: 0.5% solution of the etanercept in formulation buffer
Injection 3: 1.0% solution of the etanercept in formulation buffer formulated in a 1:1 mixture (v/v) FCA/distilled water.

Injections 1 and 2 were given close to each other nearest to the head, while injection 3 was given at the caudal part of the test area. Approximately 24 and 48 h after intradermal injection, the animals were observed for pathological alterations, if any, at the test substance injection sites according to the scale given in the Table 1.

Topical Induction (Day 6 and 7)

The induction site was clipped free of hair. Since, the test substance was found to be not a skin irritant, 0.5 ml of 10% sodium lauryl sulphate in vaseline was applied to the test area of control and treated groups, in order to create a local irritation on day 6. On the next day (day 7), a filter paper patch (Whatman No.4; approximate size 2cm x 2cm) was loaded with test substance (1.0% solution). The loaded patch was applied to the clipped induction site and held in place with adhesive tape. The patch was covered with occlusive dressings and secured with adhesive band in a double layer around the shoulder region. Approximately 24 h after application, all occlusive dressings were removed. The challenge sites were gently swabbed using cotton wool soaked in distilled water to remove excess test substance. Care was taken not to alter the existing skin response. The position of the challenge sites was identified using a black indelible marker pen.

Evaluation of Challenge Reactions

Approximately 21 h after removal of patches, the challenge test sites were clipped free of hair and approximately 48 and 72 h after application of challenge patch, the degree of erythema and edema were evaluated according to the Table 1.

Observations

Body weight

Body weight of individual animal was recorded prior to the induction exposure and
at the end of the experimental period.

**Toxicity Signs**

Animals were observed for clinical signs of toxicity of convulsion, coma, death, eschar formation, exophthalmos, hyperactivity, piloerection, polyuria, prostration, wound formation, alopecia, diarrhea, lacrimation, respiratory distress, catalepsy, chromodacryorrhea, dullness, edema, nasal irritation, nostril discharge, rigidity, salivation, change of body coat color, erythema, paralysis and tremor daily throughout the experimental period.

**Euthanasia**

On termination, the experiment animals were euthanized by using CO$_2$.

**Results and Discussion**

**Body weight**

Normal body weight was observed in the test substance treated guinea pigs and control group animals (Table 2).

**Toxicity Signs**

No clinical signs of toxicity were observed. All animals were apparently healthy throughout the experiment.

**Skin Reactions**

None of the animals in treatment and control groups presented any skin reaction at 48 and 72 h after application of the challenge patch. Since none of the animals in treatment and control groups presented any erythematous responses, a grade of '0' was given to all the animals at both the time points of observation after the challenge patch application (Table 3).

Non-communicable chronic inflammatory diseases like IBD, neoplasm, diabetic complications and degenerative disorders of lungs, heart and brain have been observed to have increasing incidences and are attributed as the major cause of death, globally. Unhealthy food patterns, smoking, lack of physical activity, stress, radiation exposure and environmental pollutants are regarded to be the frequent causes of chronic disorders. Majority of such risk factors have been observed to be closely related to chronic inflammation that can result in several chronic disorders (Prasad and Aggarwal, 2014). From the study it was concluded that etanercept was not a skin sensitizer in guinea pigs. As per the Centers for Disease Control and Prevention, USA, such disorders result in around 63% of total mortality globally and around two-thirds of mortality (17 lakhs every year) in the United States. Traditionally, the treatment of chronic inflammatory disease has been to target the inflammatory response. The various substances that can achieve the anti-inflammatory effect have in common that they inhibit the activity of the immune system, although for many of them, the exact mechanism remains elusive. The main drawback with immunosuppressive treatment is the increased risk of infection arising from the manipulation of the immune system. It is believed that corticosteroids act by entering into immune cells to inhibit genes that code for pro-inflammatory cytokines, among them mainly, TNF (Spies et al., 2010).

Advances in our understanding of the immune system, as well as the advent of the era of biotechnology, have triggered great interest in the development of new therapies for inflammatory disorders. Our better understanding of these disorders has also shifted treatment strategy from a more conservative approach to a much more aggressive one. Although conventional
Treatment modalities remain the mainstay and are sufficient and appropriate in many and may be the majority of patients, we have clearly entered the “biologic” treatment era. Compared to conventional treatment, these agents target the immune system more selectively and therefore have fewer non-specific side effects, although many cytokines are certainly pleiotropic.

The introduction of anti-TNF treatment has been a significant addition to the available treatment regimens of chronic inflammatory disease and has also added valuable insight in disease pathogenesis (Sfikakis, 2010). These drugs are aimed to particularly target TNF that plays the central role in chronic inflammation and currently, 5 drugs namely, infliximab, adalimumab, etanercept, certolizumab-pegol and golimumab are used. Despite their common target, their effects also differ. Etanercept is effective for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and psoriasis, but not for Crohn’s disease or ulcerative colitis (Sfikakis, 2010 and Sandborn et al., 2001). Common for all anti-TNF substances is that their indication depends on disease severity, and they are generally indicated in moderate to severe disease.

Etanercept is a biopharmaceutical used in the treatment of several disorders of inflammation as well as autoimmunity through the inhibition of TNF-α. Disorders of autoimmunity include conditions that arise as a result of immunological response against one’s own antigens. TNFα is a cytokine secreted by the T cells, B cells as well as the mononuclear phagocytes. TNFα promotes inflammation further through the recruitment of leucocytes to the zone of inflammation and through the initiation and activation of other molecular pathways that amplify inflammatory response. Etanercept causes the inhibition of TNFα and thereby has the potential to treat such disorders (Feldmann and Maini, 2003). It is a fusion protein synthesized through recombinant DNA technology which binds the tumor necrosis factor receptors (TNFRs) to the constant domain of the immunoglobulin, Ig G1.

Preclinical toxicology evaluation of biopharmaceuticals, however, present significant challenges to human risk assessment owing to their innovative and complex nature (Brennan et al., 2015). The major objectives of preclinical assessment of biopharmaceuticals are (1) to identify target organs showing toxic effects and to ascertain whether the toxic effects are reversible after the cessation of drug administration, (2) to identify a safe starting dose in case of human Phase I clinical trials and for further dose escalation, (3) provision of data to assist the monitoring of safety parameters in human trials and (4) provision of safety data to strengthen the claims on the product label (Cavagnaro, 2008).

Table 1: Skin reaction grading scale*

| Observations                        | Grades |
|-------------------------------------|--------|
| No visible change                   | 0      |
| Discrete or patchy erythema         | 1      |
| Moderate and confluent erythema     | 2      |
| Intense erythema and swelling       | 3      |

*Magnusson and Kligman grading scale for the evaluation of challenge patch test reactions
**Table 2** Individual Animal Body Weight Data

| Group                        | Animal No. | Sex   | Body weight (g) |     |     |
|------------------------------|------------|-------|-----------------|-----|-----|
|                              |            |       | Day 0           | Day 24|
| **G1 - Control Group**       |            |       |                 |     |     |
|                              | SS 01      | Male  | 256             | 279 |
|                              | SS 02      |       | 272             | 295 |
|                              | SS 03      |       | 273             | 298 |
|                              | SS 04      |       | 262             | 286 |
|                              | SS 05      |       | 257             | 280 |
|                              | SS 06      |       | 258             | 281 |
| **G1 - Control Group**       |            | Female| 269             | 294 |
|                              | SS 07      |       | 255             | 276 |
|                              | SS 08      |       | 265             | 288 |
|                              | SS 09      |       | 256             | 286 |
|                              | SS 10      |       | 256             | 284 |
|                              | SS 11      |       | 256             | 288 |
|                              | SS 12      |       | 256             | 288 |
| **G2 – Treatment Group**     |            | Male  | 258             | 279 |
| (Etanercept @ 0.5% and 1.0% | SS 13      |       | 244             | 268 |
| concentration)               | SS 14      |       | 246             | 268 |
|                              | SS 15      |       | 266             | 288 |
|                              | SS 16      |       | 268             | 285 |
|                              | SS 17      |       | 246             | 269 |
|                              | SS 18      |       | 255             | 285 |
|                              | SS 19      |       | 253             | 284 |
|                              | SS 20      |       | 266             | 288 |
|                              | SS 21      |       | 255             | 278 |
| **G2 – Treatment Group**     |            | Female| 264             | 284 |
| (Etanercept @ 0.5% and 1.0% | SS 23      |       | 266             | 288 |
| concentration)               | SS 24      |       | 248             | 270 |
|                              | SS 25      |       | 259             | 275 |
|                              | SS 26      |       | 265             | 290 |
|                              | SS 27      |       | 266             | 291 |
|                              | SS 28      |       | 259             | 275 |
|                              | SS 29      |       | 258             | 276 |
|                              | SS 30      |       | 264             | 284 |
|                              | SS 31      |       | 259             | 279 |
|                              | SS 32      |       |                 |     |
Table.3 Evaluation Of Challenge Patch Test Reactions

| Group                  | Animal No. | Sex | Hours (after application of challenge patch) |
|------------------------|------------|-----|--------------------------------------------|
|                        |            |     | 48                                         | 72                                         |
| **G1 - Control Group** |            |     |                                             |                                             |
| SS 01                  | Male       | 0   | 0                                          | 0                                          |
| SS 02                  |            | 0   | 0                                          | 0                                          |
| SS 03                  |            | 0   | 0                                          | 0                                          |
| SS 04                  |            | 0   | 0                                          | 0                                          |
| SS 05                  |            | 0   | 0                                          | 0                                          |
| SS 06                  |            | 0   | 0                                          | 0                                          |
| **G1 - Control Group** |            |     |                                             |                                             |
| SS 07                  | Female     | 0   | 0                                          | 0                                          |
| SS 08                  |            | 0   | 0                                          | 0                                          |
| SS 09                  |            | 0   | 0                                          | 0                                          |
| SS 10                  |            | 0   | 0                                          | 0                                          |
| SS 11                  |            | 0   | 0                                          | 0                                          |
| SS 12                  |            | 0   | 0                                          | 0                                          |
| **G2 – Treatment Group** |            |     |                                             |                                             |
| (Etanercept @ 0.5% and 1.0% concentration) |            |     |                                             |                                             |
| SS 13                  | Male       | 0   | 0                                          | 0                                          |
| SS 14                  |            | 0   | 0                                          | 0                                          |
| SS 15                  |            | 0   | 0                                          | 0                                          |
| SS 16                  |            | 0   | 0                                          | 0                                          |
| SS 17                  |            | 0   | 0                                          | 0                                          |
| SS 18                  |            | 0   | 0                                          | 0                                          |
| SS 19                  |            | 0   | 0                                          | 0                                          |
| SS 20                  |            | 0   | 0                                          | 0                                          |
| SS 21                  |            | 0   | 0                                          | 0                                          |
| SS 22                  |            | 0   | 0                                          | 0                                          |
| **G2 – Treatment Group** |            |     |                                             |                                             |
| (Etanercept @ 0.5% and 1.0% concentration) |            |     |                                             |                                             |
| SS 23                  | Female     | 0   | 0                                          | 0                                          |
| SS 24                  |            | 0   | 0                                          | 0                                          |
| SS 25                  |            | 0   | 0                                          | 0                                          |
| SS 26                  |            | 0   | 0                                          | 0                                          |
| SS 27                  |            | 0   | 0                                          | 0                                          |
| SS 28                  |            | 0   | 0                                          | 0                                          |
| SS 29                  |            | 0   | 0                                          | 0                                          |
| SS 30                  |            | 0   | 0                                          | 0                                          |
| SS 31                  |            | 0   | 0                                          | 0                                          |
| SS 32                  |            | 0   | 0                                          | 0                                          |

*Number indicates the skin reaction scoring as mentioned in Table 1.

The preclinical toxicity evaluations have to be conducted using young healthy rodents / non-rodents complying with the regulatory guidelines of Good Laboratory Practice.
These studies do not characterize pharmacology, which is generally analysed using specifically designed efficacy studies before the initiation of GLP toxicity evaluations. These studies are, in general, performed in 2 species, a rodent species and a non-rodent species (ICH, 2009).

The objective of such investigations is to assess the possible target organs of toxicity as well as to ascertain the dose wherein adverse effects are absent. The ratio of the maximum tolerated dose to that of the no observed adverse effect level gives us a measure of safety margin of the test item. Toxicity is classified as either ‘on-target’, i.e., direct pharmacological effects of the drug, or ‘off-target’, i.e., indirect non-pharmacological effects (Guengerich, 2011). Skin sensitization test describes an immunological process whereby excessive response to any allergen is induced. To determine the skin sensitization potential of the etanercept, guinea pigs were selected as the model. All treated animals showed normal body weight gain and no adverse skin reaction was observed in the experimental group after the challenge at both the time points of observation. Skin sensitization potential study of etanercept in guinea pigs revealed no clinical signs of toxicity. No skin reaction was observed in the experimental group after the challenge at both the time points of observation. Normal body weight was observed among all the animals of the treated groups. Etanercept was found to be safe and well tolerated in this study and was concluded to be a non-sensitizer to the skin of the guinea pigs.

References

Basketter D, Casati S, Gerberick F, Griem P, Philips B, Worth A (2004). Skin Sensitisation. http://ec.europa.eu/consumers/sectors/cosmetics/files/doc/antest/(5)_chapter_3/4_skin_sensitisation_(final)_(1).pdf. Accessed on 13th August, 2017.

Basketter D, Scholes EW (1992). Comparison of the local lymph node assay with the guinea-pig maximization test for the detection of a range of contact allergens. Food and Chem Toxicol 30:65-69.

Brennan FR, Baumann A, Blaich G, de Haan L, Fagg R, Kiessling A, Kronenberg S, Locher M, Milton M, Tibbitts J, Ulrich P, Weir L (2015). Nonclinical safety testing of biopharmaceuticals - Addressing current challenges of these novel and emerging therapies. Regul Toxicol Pharmacol. 73(1):265-275.

Cavagnararo JA (2008). Preclinical Safety Evaluation of Biopharmaceuticals a Science-based Approach to Facilitating Clinical Trials. John Wiley & Sons, Inc., Hoboken, New Jersey. 1070p.

FDA (2010). Guidance for Industry M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals.

FDA (2011). Tumor Necrosis Factor (TNF) Blockers. Available at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm109340.htm. Accessed on 16th August 2017.

Feldmann M, Maini RN (2003). TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med. 9:1245-1250.

Guengerich F (2011). Mechanisms of drug toxicity and relevance to pharmaceutical development. Drug Metab Pharmacokinet. 26:3-14.

ICH (2009). M3 (R2) - Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals.
Kimber I, Basketter DA, Berthold K, Butler M, Garrigue JL, Lea L, Newsome C, Roggeband R, Steiling W, Stropp G, Waterman S, Wiemann C (2001). Skin sensitization testing in potency and risk assessment. ToxicolScit59):2:198-208.

Magnusson B, Kligman AM (1969). The identification of contact allergens by animal assay. The guinea pig maximisation test. J Invest Dermatol52:2:268.

OECD 1998. OECD Principles on Good Laboratory Practice.http://www.oecd.org/document/1/0,3746, en_2649_37465_48477249_1_1_1_37465, 00.html. Accessed on 13th February, 2012.

Prasad S, Aggarwal BB (2014). Chronic diseases caused by chronic inflammation require chronic treatment: anti-inflammatory role of dietary spices. J Clin Cell Immunol5:2:238.

Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DJ, Baerg RD, Tremaine WJ, Johnson T, Diehl NN, Zinsmeister AR (2001). Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121(5):1088-1094.

Sfikakis PP (2010). The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. In. TNF Pathophysiology. Molecular and Cellular Mechanisms, Kollias G and Sfikakis PP (eds). Curr Dir Autoimmun Karger, Basel 11:180-210.

Spies CM, Bijlsma JW, Burmester GR, Buttgereit F (2010). Pharmacology of glucocorticoids in rheumatoid arthritis. Curr Opin Pharmacol 10(3):302-307.

Tziakas D, Chalikias G, Parissis JT, Hatzinikolaou H, Stakos D, Papadopoulou E, Kortsaris A, Hatseras D (2004). Prolonged activation of tumor necrosis factor (TNF)-alpha and its soluble receptors in chronic heart failure patients both in the compensated and decompensated state. Interplay between their levels and metalloproteinase-3. Eur Cytokine Netw 15(3):231-239.

Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ (1999). A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Eng J Med. 340(4):253-259.

How to cite this article:

Selvam, G., S. Bhuvana, P.C. Prabu and Sadasivan Pillai, K. 2020. Study on Skin Sensitization Potential of an Anti - tumor necrosis factor -alpha receptor fusion protein in Guinea pigs. Int.J.Curr.Microbiol.App.Sci. 9(06): 4273-4282. doi: https://doi.org/10.20546/ijcmas.2020.906.501